Risk-Based Data Management: Moving Beyond Traditional Data Cleaning

In a recent MMS webinar, Lucy Sutton, Vice President of Account Management, sat down with Doreen Van Huyssteen, Director of Clinical Data Management, to explore how risk-based data management is changing the way sponsors approach clinical trial oversight. Their discussion covered the evolution of data management practices, the importance of cross-functional collaboration, emerging technologies, and practical strategies for implementing a risk-based approach.

Clinical trials generate vast amounts of data, yet not all data carries the same level of importance when it comes to demonstrating safety and efficacy. As study designs become more complex and data sources continue to expand, sponsors are increasingly recognizing the limitations of traditional data management approaches. As Doreen explained during the webinar, risk-based data management offers a more focused approach, helping organizations prioritize the data that matters most while improving efficiency and maintaining study quality.

Why Traditional Data Management Is No Longer Enough

Historically, clinical data management has relied on reviewing and cleaning all data with the same level of scrutiny. While this approach was appropriate for many studies, it can become inefficient and resource-intensive in today’s increasingly complex development environment.

Risk-based data management takes a different approach. Rather than treating every data point equally, it prioritizes the variables that are critical to study outcomes, patient safety, and regulatory decision-making. This requires data management teams to become involved earlier in study planning, helping identify risks, assess critical data, and align operational strategies before database build activities begin.

The result is a more targeted framework that enables teams to focus effort where it delivers the greatest value.

Building the Foundation for Effective RBDM

Successful implementation of risk-based data management starts with process. While technology is important, well-defined processes remain the foundation that supports effective risk-based decision-making.

Organizations adopting risk-based data management often need to rethink established workflows, refine review plans, and create clear frameworks for identifying and managing risk throughout the study lifecycle. Guidance such as ICH E6(R3) encourages a risk-based approach, but widespread adoption requires organizations to make both operational and cultural changes.

Rather than attempting a complete transformation overnight, sponsors may benefit from introducing risk-based principles gradually, refining processes over time as teams gain experience and confidence.

The Importance of Cross-Functional Collaboration

Risk-based approaches may not succeed in isolation. Effective collaboration between clinical operations, data management, biostatistics, statistical programming, pharmacovigilance, and other stakeholders is essential.

When communication breaks down, teams can unknowingly duplicate effort, create inefficiencies, or overlook critical risks. For example, multiple functions may spend time independently reviewing the same data, while important variables could be incorrectly classified if key stakeholders are not involved early in planning discussions.

Cross-functional collaboration helps ensure that risks are identified collectively, review activities are aligned, and decision-making is informed by a complete understanding of the study.

Rethinking Data Review Through Data Tiering

One of the key operational shifts in risk-based data management is adopting a tiered approach to data review. Rather than applying identical review frequencies and query management processes across all data, organizations can adjust review intensity based on the importance of specific variables.

Critical data may require frequent review and rapid query resolution, while routine or lower-risk data can be reviewed using proportionate processes. This approach allows teams to allocate resources more effectively while still maintaining comprehensive oversight across the study.

Leveraging Technology to Enable Better Decisions

While risk-based data management starts with people and processes, the right technology can help organizations operationalize these strategies more effectively. Modern studies generate data from multiple sources, making it increasingly difficult to identify meaningful trends and potential risks through manual review alone.

To support a risk-based approach, sponsors need tools that move beyond simple data visualization and provide actionable insights. This includes the ability to consolidate data from multiple sources, monitor study health in near real time, identify emerging risks, and support informed decision-making across functional teams.

MMS’s Datacise® platform was designed with these objectives in mind. Its configurable dashboards enable sponsors to visualize critical study metrics, monitor trends, and gain a more holistic view of study performance. During the webinar, Datacise was highlighted for its ability to integrate diverse data streams and present role-specific views, helping clinical operations, data management, safety, and other stakeholders focus on the information most relevant to their responsibilities.

The platform also incorporates AI-enabled capabilities, including the ability to query data using natural language through its “Ask the Data” functionality. This allows users to quickly investigate specific questions and uncover insights that may otherwise require significant manual effort. As organizations continue to embrace risk-based operating models, technologies such as Datacise can help transform large volumes of trial data into meaningful intelligence that supports proactive oversight and better decision-making.

A Practical Starting Point for Sponsors

For organizations interested in adopting risk-based data management, the most important advice is simple: start small and build from a strong process foundation.

Sponsors do not need to implement every aspect of RBDM at once. Instead, they can focus on introducing the elements that are most relevant to their studies, whether that involves data tiering, enhanced risk assessment, improved collaboration, or new analytical tools.

Effective risk-based data management depends on strong cross-functional collaboration, a clear understanding of study risk, and technology that enables teams to act on insights quickly.

Ultimately, effective risk-based data management is about creating a smarter, more focused approach to data review. By combining strong processes, cross-functional collaboration, and enabling technologies, sponsors can improve study oversight, reduce inefficiencies, and concentrate effort where it matters most: protecting patients and ensuring confidence in trial outcomes.